Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

Inclusion Criteria:

• Age >18 - < 95 years;

• Presence of one or more coronary artery stenosis of 50% or more in a native coronaryartery or in a saphenous venous or arterial bypass conduit suitable for coronarystent implantation. The vessel should have a reference vessel diameter of at least 2.00 mm (no limitation on the number of treated lesions, vessels, or lesion length);

• Able to provide informed consent and willing to participate in the trial.

Exclusion Criteria:

• Known intolerance to acetylsalicylic acid, P2Y12 inhibitors (clopidogrel, prasugrel,or ticagrelor), sirolimus, everolimus, or chromium-cobalt.;

• Known severe hepatic impairment Child-Pug stage C;

• Prior PCI (not related to the study) performed in the last 45 days;

• Planned non-cardiac surgery during the first month after PCI, unless dualantiplatelet therapy is maintained throughout the peri-surgical period;

• Planned coronary artery bypass graft (CABG) or any other cardiac surgery (valvularfor instance) following index PCI;

• Active major bleeding or major surgery within the last 30 days;

• Known stroke (any type) within the 30 days prior to the randomization;

• Women of childbearing potential being defined as woman from the onset ofmenstruation (menarche) until they become postmenopausal, unless they arepermanently sterile. A postmenopausal state is clarified as having no menstrualperiods for 12 consecutive months without any other medical cause. Women who haveundergone permanent sterilization methods, including hysterectomy, bilateralsalpingectomy, and bilateral oophorectomy, can be enrolled in the study

• Currently participating in another randomized controlled trial and not yet at itsprimary endpoint;

• Life expectancy less than one year due to non-cardiovascular comorbidity.